Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis-Reference-Cited by-同舟云学术

Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis

Published:2019-05 Issue:5 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Alghamdi Wael A.¹²^ORCID,Alsultan Abdullah³,Al-Shaer Mohammad H.¹^ORCID,An Guohua⁴,Ahmed Shahriar⁵,Alkabab Yosra⁶,Banu Sayera⁵,Barbakadze Ketevan⁷,Houpt Eric⁶,Kipiani Maia⁷,Mikiashvili Lali⁷,Schmidt Stephan⁸,Heysell Scott K.⁶,Kempker Russell R.⁹,Cegielski J. Peter¹⁰,Peloquin Charles A.¹^ORCID

Affiliation:

1. Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA

2. Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia

3. Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

4. Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa, USA

5. Infectious Diseases Division, International Centre for Diarrhoeal Diseases Research, Bangladesh (icddr,b), Dhaka, Bangladesh

6. Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA

7. National Center for TB and Lung Diseases (NCTLD), Tbilisi, Georgia

8. Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA

9. Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, USA

10. University of Texas Health Science Center at Tyler, Tyler, Texas, USA

Abstract

Limited pharmacokinetic/pharmacodynamic (PK/PD) data exist on cycloserine in tuberculosis (TB) patients. We pooled several studies into a large PK data set to estimate the population PK parameters for cycloserine in TB patients.

Funder

HHS | National Institutes of Health

Bill and Melinda Gates Foundation

International Science and Technology Center

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00055-19

Reference32 articles.

1. World Health Organization. 2018. Global tuberculosis report 2018. World Health Organization, Geneva, Switzerland.

2. Psychosis associated with cycloserine;Bankier RG;Can Med Assoc J,1965

3. Inhibitors of alanine racemase enzyme: a review

4. World Health Organization. 2018. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). World Health Organization, Geneva, Switzerland.

5. Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic drug monitoring in tuberculosis;European Journal of Clinical Pharmacology;2024-09-06

2. Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-08

3. Possibilities of Using Nootropic Drugs to Reduce Neurotoxic Reactions Caused by Anti-tuberculosis Drugs in Experimental Conditions;Tuberculosis and Lung Diseases;2024-07-04

4. Current Drug Delivery Strategies to Design Orally Dissolving Formulations to Target Tuberculosis: A Futuristic Review;Drug Delivery Letters;2024-06

5. Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis of Second-Line Anti-Tubercular Drugs in Indian Children with Multi-Drug Resistance;Indian Journal of Pediatrics;2024-05-28